<form id="dvzj5"><form id="dvzj5"><th id="dvzj5"></th></form></form><form id="dvzj5"><nobr id="dvzj5"><th id="dvzj5"></th></nobr></form>

    <form id="dvzj5"></form>

      <form id="dvzj5"><form id="dvzj5"><nobr id="dvzj5"></nobr></form></form>

            18611095289

            product

            產品中心

            當前位置:首頁產品中心Biomedica Gruppe骨代謝DKK-1 ELISA Kit

            DKK-1 ELISA Kit
            產品簡介:

            Cat.No.:BI-20413
            應用領域:
            1)骨代謝疾病
            2)Wnt信號通路
            試劑盒特點:
            檢測方法:夾心ELISA,HRP/TMB顯色
            樣本類型:血清
            樣品量:20ul/test
            標準品范圍:0-160 pmol/L
            檢測靈敏度:1.7pmol/L
            孵育條件:2h/1h/30min

            產品型號:

            更新時間:2024-12-08

            廠商性質:代理商

            訪問量:1773

            服務熱線

            01084640949

            立即咨詢
            產品介紹

            DKK-1檢測試劑盒

            直接測定,無需樣本稀釋

            貨號:BI-20413  

            DKK-1 Wnt 信號通路的抑制劑

            BI-20413BI-20412對比

            檢測特點

            BI-20413

            BI-20412

            孵育時間

            2h/1h/30min

            overnight

            樣品處理

            直接測定

            需要1:4稀釋

            標準品范圍

            0-160pmol/L

            0-50pmol/L

            應用領域

            1. 骨代謝疾病
            2. Wnt信號通路

            試劑盒特點:

            檢測方法:夾心ELISA,HRP/TMB顯色

            樣本類型:血清

            樣品量:20ul/test

            標準品范圍:0-160 pmol/L

            檢測靈敏度:1.7pmol/L

            孵育條件:2h/1h/30min

            產品優勢:

            1. 當日即可檢測
            2. 直接測定,不許樣品稀釋。
            3. 樣本需求量少,只需:20ul
            4. 標準品范圍廣
            5. 充分證實可用于人血清樣本檢測
            6. 6個標準品+1個對照(均為血清基質)
            7. 操作流程簡單

            參考文獻

            1

            Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin

            and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A

            Randomized, Head-to-Head Clinical Trial. Athanasios D. Anastasilakis, et al.

            J. Clin. Endocrinol. Metab., Aug 2013; 98: 3206 - 3212.

            2

            Elevated Serum Dickopff-1 Levels Increase Risk of Hip and Vertebral Fracture in Older Caucasian Women. Aarthi Arasu,et al. Endocr. Rev., Jun 2013; 34: SAT-224.

            3

            Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Diederik P C de Rooy,et al. Ann Rheum Dis, May 2013; 72: 769 - 775.

            4

            High dickkopf-1 levels in sera and leukocytes from children with 21-

            hydroxylase deficiency on chronic glucocorticoid treatment. Giacomina Brunetti,et al. Am J Physiol Endocrinol Metab, Mar 2013; 304: E546 - E554.

            5

            Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. D Gatti,et al. J Bone Miner Res, Nov 2012; 27(11): 2259-63. 

            6

            Sclerostin Levels Associated with Inhibition of the Wnt/β-Catenin Signaling and Reduced Bone Turnover in Type 2 Diabetes Mellitus. Agostino Gaudio,et al. J. Clin. Endocrinol. Metab., Oct 2012; 97: 3744 - 3750.

            7

            Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans

            Cell Histiocytosis. Polyzois Makras,et al. J. Clin. Endocrinol. Metab., Apr 2012; 97: E618 - E621

            8

            High level of functional dickkopf-1 predicts protection from syndesmophyte

            formation in patients with ankylosing spondylitis. Gisela Ruiz Heiland,et al. Ann Rheum Dis, Apr 2012; 71: 572 - 574. 

            9

            Assessment of circulating Dickkopf-1 with a new two-site immunoassay in

            healthy subjects and women with breast cancer and bone metastases. N Voorzanger-Rousselot, et al. Calcif Tissue Int, May 1, 2009; 84(5): 348-354

            10

            Circulating Dickkopf-1 and Radiological Progression in Patients with Early

            Rheumatoid Arthritis Treated with Etanercept. Patrick Garnero,et al. J Rheumatol, Oct 2008.

            11

            Increased Sclerostin Serum Levels Associated with Bone Formation and Resorption Markers in Patients with Immobilization-Induced Bone Loss. Agostino Gaudio,et al. J. Clin. Endocrinol. Metab., May 2010; 95: 2248 - 2253.

            12

            High Serum Sclerostin Correlates with Advanced Stage, Increased Bone

            Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma. Evangelos Terpos,et al. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 425.

            13

            The Effect of Zoledronic Acid on Serum Dickkopf-1, Osteoprotegerin, and RANKL

            in Patients with Paget's Disease of Bone. S A Polyzos, et al. Horm Metab Res, Aug 2009 

            14

            Glucocorticoids Attenuate the Stimulatory Effect on Bone Formation by

            Bortezomib. Thomas Lund,et al. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 5183. 

            在線留言

            留言框

            • 產品:

            • 您的單位:

            • 您的姓名:

            • 聯系電話:

            • 常用郵箱:

            • 省份:

            • 詳細地址:

            • 補充說明:

            • 驗證碼:

              請輸入計算結果(填寫阿拉伯數字),如:三加四=7

            服務熱線
            18611095289

            掃碼加微信

            精品国产国产综合精品_白丝女班长被弄得娇喘不停_色综合九九_国产怡春院无码一区二区

              <form id="dvzj5"><form id="dvzj5"><th id="dvzj5"></th></form></form><form id="dvzj5"><nobr id="dvzj5"><th id="dvzj5"></th></nobr></form>

              <form id="dvzj5"></form>

                <form id="dvzj5"><form id="dvzj5"><nobr id="dvzj5"></nobr></form></form>

                      >